As part of the agreement, which was signed in May 2025, 3SBio will receive $1.25bn, along with a $100m equity investment from ...

Pfizer Inc. (NYSE: PFE) announced today the completion of a global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK) ...

Pfizer agreed to an upfront payment of US$1.25 billion, US$150 million for mainland rights and a US$100 million equity ...

Moderna has scrapped plans to build an mRNA plant in Japan. Otsuka and Lundbeck's proposal for Rexulti as part of a PTSD ...

Pfizer Inc. has completed the previously announced global, ex-China, licensing agreement with 3SBio Inc., which grants Pfizer exclusive rights for the development, manufacturing and commercialization ...

HONG KONG, Aug. 24, 2023 /PRNewswire/ -- Chinese leading biopharmaceutical company 3SBio (01530.HK) today released its 2023 interim results. Revenue in the first half of 2023 reached approximately ...

SHANGHAI, Sept. 11, 2019 /PRNewswire/ -- According to Morgan Stanley Capital International's (MSCI) latest set of ESG ratings, 3SBio has been upgr ...

NuLeusin, 3SBio’s second generation IL-2 drug, would essentially be a new market for 3SBio (the company does have a legacy IL-2 product, but its sales are negligible).

3SBio is a leading biotech drugmaker in China. It is one of the earliest biologics innovators in the country, launching EPIAO in 1998 and TPIAO in 2005, which are market-leading innovative drugs.

3SBio Inc. (SSRX) reported fourth quarter financial results that beat the previous year’s numbers by a substantial amount, but still fell short of estimates. Adding insult to the injury, the ...

3SBio is a leading biopharmaceutical company in China. It is one of the earliest biologics innovators in the country, launching EPIAO in 1998 and TPIAO in 2005. The current portfolio is older ...

3SBio Inc. has agreed to be taken private by Decade Sunshine Ltd. in a deal that values the China-based biotechnology company at about $350 million. Under the deal's terms, 3SBio will get $2.20 in ...